nach oben

Erschienen in:

15.01.2018 | Koronare Herzerkrankung | CME

Prävention von Herz-Kreislauf-Erkrankungen

verfasst von: Dr. med. J. H. Prochaska, N. Arnold, C. Jünger, T. Münzel, Univ.-Prof. Dr. med. P. S. Wild

Erschienen in: Herz | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das Auftreten von kardiovaskulären Erkrankungen kann durch Früherkennung und gezielte Behandlung von Risikofaktoren und der subklinischen Erkrankung reduziert werden. Die Maßnahmen auf dem Gebiet der Primärprävention umfassen vielfältige Möglichkeiten zur erfolgreichen Intervention. Neben einer medikamentösen Therapie sind v. a. lebensstilverändernde Maßnahmen wie körperliche Aktivität, Normalisierung des Körpergewichts, konsequente Nikotinabstinenz sowie die Berücksichtigung psychosozialer Aspekte zentrale Kernbestandteile von Präventionsprogrammen. Versorgungsmedizinische Untersuchungen zeigen, dass Risikofaktoren oft unerkannt bleiben bzw. das volle Potenzial des Managements von Risikofaktoren noch nicht optimal ausgeschöpft wird. Hierbei kommt v. a. der Motivation und Therapieadhärenz der Patienten eine entscheidende Rolle zu.

GBD 2016 Disease and Injury Incidence and Prevalence Collaborators (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet 390(10100):1211–1259CrossRef

Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105(9):1135–1143CrossRefPubMed

Yusuf S, Hawken S, Ounpuu S et al (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364(9438):937–952CrossRefPubMed

Khot UN, Khot MB, Bajzer CT et al (2003) Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 290(7):898–904CrossRefPubMed

Criqui MH, Barrett-Connor E, Holdbrook MJ et al (1980) Clustering of cardiovascular disease risk factors. Prev Med 9(4):525–533CrossRefPubMed

Piepoli MF, Hoes AW, Agewall S et al (2016) 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European association for cardiovascular prevention & rehabilitation (EACPR). Eur Heart J 37(29):2315–2381CrossRefPubMedPubMedCentral

Mortensen MB, Nordestgaard BG, Afzal S et al (2017) ACC/AHA guidelines superior to ESC/EAS guidelines for primary prevention with statins in non-diabetic Europeans: the Copenhagen general population study. Eur Heart J 38(8):586–594PubMed

Ray KK, Kastelein JJ, Boekholdt SM et al (2011) The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J 35(15):960–968CrossRef

Lewington S, Clarke R, Qizilbash N et al (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360(9349):1903–1913CrossRefPubMed

10.

Law MR, Morris JK, Wald NJ (2009) Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338:b1665CrossRefPubMedPubMedCentral

11.

Vasan RS, Beiser A, Seshadri S et al (2002) Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham heart study. JAMA 287(8):1003–1010CrossRefPubMed

12.

Vasan RS, Larson MG, Leip EP et al (2001) Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 345(18):1291–1297CrossRefPubMed

13.

Schwartz JE, Burg MM, Shimbo D et al (2016) Clinic blood pressure underestimates ambulatory blood pressure in an untreated employer-based US population: results from the masked hypertension study. Circulation 134(23):1794–1807CrossRefPubMedPubMedCentral

14.

Pierdomenico SD, Cuccurullo F (2011) Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: an updated meta analysis. Am J Hypertens 24(1):52–58CrossRefPubMed

15.

Wright JT Jr., Williamson JD, Whelton PK et al (2015) A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373(22):2103–2116CrossRefPubMed

16.

Ettehad D, Emdin CA, Kiran A et al (2016) Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 387(10022):957–967CrossRefPubMed

17.

Egan BM, Zhao Y, Axon RN (2010) US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA 303(20):2043–2050CrossRefPubMed

18.

Mancia G, Fagard R, Narkiewicz K et al (2013) 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34(28):2159–2219CrossRefPubMed

19.

Thom S, Poulter N, Field J et al (2013) Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 310(9):918–929CrossRefPubMed

20.

Appel LJ, Brands MW, Daniels SR et al (2006) Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension 47(2):296–308CrossRefPubMed

21.

Chobanian AV, Bakris GL, Black HR et al (2003) The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289(19):2560–2572CrossRefPubMed

22.

Wilson PW, Kannel WB, Anderson KM (1985) Lipids, glucose intolerance and vascular disease: the Framingham study. Monogr Atheroscler 13:1–11PubMed

23.

Grossmann V, Schmitt VH, Zeller T et al (2015) Profile of the immune and inflammatory response in individuals with prediabetes and type 2 diabetes. Diabetes Care 38(7):1356–1364CrossRefPubMed

24.

Ryden L, Grant PJ, Anker SD et al (2013) ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34(39):3035–3087CrossRefPubMed

25.

Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346(6):393–403CrossRefPubMed

26.

Howard BV, Best LG, Galloway JM et al (2006) Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diabetes Care 29(2):391–397CrossRefPubMed

27.

Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117–2128CrossRefPubMed

28.

Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375(4):311–322CrossRefPubMedPubMedCentral

29.

Catapano AL, Graham I, De Backer G et al (2016) 2016 ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 253:281–344CrossRefPubMed

30.

Baigent C, Keech A, Kearney PM et al (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493):1267–1278CrossRefPubMed

31.

Catapano AL, Graham I, De Backer G et al (2016) 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 37(39):2999–3058CrossRefPubMed

32.

Berrington de Gonzalez A, Hartge P, Cerhan JR et al (2010) Body-mass index and mortality among 1.46 million white adults. N Engl J Med 363(23):2211–2219CrossRefPubMed

33.

Robinson JG, Farnier M, Krempf M et al (2015) Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372(16):1489–1499CrossRefPubMed

34.

Sabatine MS, Giugliano RP, Keech AC et al (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376(18):1713–1722CrossRefPubMed

35.

Nordestgaard BG, Varbo A (2014) Triglycerides and cardiovascular disease. Lancet 384(9943):626–635CrossRefPubMed

36.

Waldeyer C, Makarova N, Zeller T et al (2017) Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium. Eur Heart J 38(32):2490–2498CrossRefPubMed

37.

Voight BF, Peloso GM, Orho-Melander M et al (2012) Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380(9841):572–580CrossRefPubMedPubMedCentral

38.

Nordestgaard BG, Chapman MJ, Ray K et al (2010) Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 31(23):2844–2853CrossRefPubMedPubMedCentral

39.

Prescott E, Hippe M, Schnohr P et al (1998) Smoking and risk of myocardial infarction in women and men: longitudinal population study. BMJ 316(7137):1043–1047CrossRefPubMedPubMedCentral

40.

Ott A, Slooter AJ, Hofman A et al (1998) Smoking and risk of dementia and Alzheimer’s disease in a population-based cohort study: the Rotterdam study. Lancet 351(9119):1840–1843CrossRefPubMed

41.

Barone-Adesi F, Vizzini L, Merletti F et al (2006) Short-term effects of Italian smoking regulation on rates of hospital admission for acute myocardial infarction. Eur Heart J 27(20):2468–2472CrossRefPubMed

42.

Lampert T, von der Lippe E, Muters S (2013) Prevalence of smoking in the adult population of Germany: results of the German health interview and examination survey for adults (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 56(5–6):802–808CrossRefPubMed

43.

He J, Vupputuri S, Allen K et al (1999) Passive smoking and the risk of coronary heart disease – a meta-analysis of epidemiologic studies. N Engl J Med 340(12):920–926CrossRefPubMed

44.

Qasim H, Karim ZA, Rivera JO et al (2017) Impact of electronic cigarettes on the cardiovascular system. J Am Heart Assoc. https://doi.org/10.1161/jaha.117.006353 PubMedPubMedCentral

45.

Benowitz NL, Fraiman JB (2017) Cardiovascular effects of electronic cigarettes. Nat Rev Cardiol 14(8):447–456CrossRefPubMed

46.

Mons U, Muezzinler A, Gellert C et al (2015) Impact of smoking and smoking cessation on cardiovascular events and mortality among older adults: meta-analysis of individual participant data from prospective cohort studies of the CHANCES consortium. BMJ 350:h1551CrossRefPubMedPubMedCentral

47.

Taylor GMJ, Taylor AE, Thomas KH et al (2017) The effectiveness of varenicline versus nicotine replacement therapy on long-term smoking cessation in primary care: a prospective cohort study of electronic medical records. Int J Epidemiol. https://doi.org/10.1093/ije/dyx109

48.

Finucane MM, Stevens GA, Cowan MJ et al (2011) National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 377(9765):557–567CrossRefPubMedPubMedCentral

49.

Wellen KE, Hotamisligil GS (2003) Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 112(12):1785–1788CrossRefPubMedPubMedCentral

50.

Despres JP, Lemieux I (2006) Abdominal obesity and metabolic syndrome. Nature 444(7121):881–887CrossRefPubMed

51.

Tang WH, Hazen SL (2017) The gut microbiome and its role in cardiovascular diseases. Circulation 135(11):1008–1010CrossRefPubMed

52.

Kim SH, Despres JP, Koh KK (2016) Obesity and cardiovascular disease: friend or foe? Eur Heart J 37(48):3560–3568CrossRefPubMed

53.

Sattelmair J, Pertman J, Ding EL et al (2011) Dose response between physical activity and risk of coronary heart disease: a meta-analysis. Circulation 124(7):789–795CrossRefPubMedPubMedCentral

54.

Bangalore S, Fayyad R, Laskey R et al (2017) Body-weight fluctuations and outcomes in coronary disease. N Engl J Med 376(14):1332–1340CrossRefPubMed

55.

O’Leary DH, Polak JF, Kronmal RA et al (1999) Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular health study collaborative research group. N Engl J Med 340(1):14–22CrossRefPubMed

56.

Chambless LE, Heiss G, Folsom AR et al (1997) Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987–1993. Am J Epidemiol 146(6):483–494CrossRefPubMed

57.

Sinning C, Wild PS, Echevarria FM et al (2011) Sex differences in early carotid atherosclerosis (from the community-based Gutenberg-Heart Study). Am J Cardiol 107(12):1841–1847CrossRefPubMed

58.

Den Ruijter HM, Peters SA, Anderson TJ et al (2012) Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA 308(8):796–803CrossRef

59.

Townsend RR, Wilkinson IB, Schiffrin EL et al (2015) Recommendations for improving and standardizing vascular research on arterial stiffness: a scientific statement from the American Heart Association. Hypertension 66(3):698–722CrossRefPubMedPubMedCentral

60.

Ben-Shlomo Y, Spears M, Boustred C et al (2014) Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol 63(7):636–646CrossRefPubMed

61.

Vlachopoulos C, Aznaouridis K, Stefanadis C (2010) Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 55(13):1318–1327CrossRefPubMed

62.

Daiber A, Steven S, Weber A et al (2017) Targeting vascular (endothelial) dysfunction. Br J Pharmacol 174(12):1591–1619CrossRefPubMed

63.

Schnabel RB, Schulz A, Wild PS et al (2011) Noninvasive vascular function measurement in the community: cross-sectional relations and comparison of methods. Circ Cardiovasc Imaging 4(4):371–380CrossRefPubMed

64.

Muiesan ML, Salvetti M, Monteduro C et al (2004) Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension 43(4):731–738CrossRefPubMed

65.

Galderisi M, Cosyns B, Edvardsen T et al (2017) Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 18(12):1301–1310PubMed

66.

McDermott MM, Greenland P, Liu K et al (2002) The ankle brachial index is associated with leg function and physical activity: the walking and leg circulation study. Ann Intern Med 136(12):873–883CrossRefPubMed

67.

Fowkes FG, Murray GD, Butcher I et al (2008) Ankle brachial index combined with Framingham risk score to predict cardiovascular events and mortality: a meta-analysis. JAMA 300(2):197–208CrossRefPubMed

68.

Haberl R, Becker A, Leber A et al (2001) Correlation of coronary calcification and angiographically documented stenoses in patients with suspected coronary artery disease: results of 1,764 patients. J Am Coll Cardiol 37(2):451–457CrossRefPubMed

69.

Tinana A, Mintz GS, Weissman NJ (2002) Volumetric intravascular ultrasound quantification of the amount of atherosclerosis and calcium in nonstenotic arterial segments. Am J Cardiol 89(6):757–760CrossRefPubMed

70.

Cao JJ, Barzilay JI, Peterson D et al (2006) The association of microalbuminuria with clinical cardiovascular disease and subclinical atherosclerosis in the elderly: the cardiovascular health study. Atherosclerosis 187(2):372–377CrossRefPubMed

71.

Shepherd J, Cobbe SM, Ford I et al (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group. N Engl J Med 333(20):1301–1307CrossRefPubMed

72.

Cushman M, Arnold AM, Psaty BM et al (2005) C‑reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation 112(1):25–31CrossRefPubMed

73.

Ridker PM, Everett BM, Thuren T et al (2017) Antiinflammatory therapy with Canakinumab for atherosclerotic disease. N Engl J Med 377(12):1119–1131CrossRefPubMed

74.

Albus C, Ladwig KH, Herrmann-Lingen C (2014) Psychocardiology: clinically relevant recommendations regarding selected cardiovascular diseases. Dtsch Med Wochenschr 139(12):596–601CrossRefPubMed

75.

Ladwig KH, Lederbogen F, Albus C et al (2014) Position paper on the importance of psychosocial factors in cardiology: update 2013. Ger Med Sci. https://doi.org/10.3205/000194 PubMedPubMedCentral

76.

Munzel T, Sorensen M, Gori T et al (2017) Environmental stressors and cardio-metabolic disease: part I‑epidemiologic evidence supporting a role for noise and air pollution and effects of mitigation strategies. Eur Heart J 38(8):550–556PubMed

77.

Peters A, von Klot S, Heier M et al (2004) Exposure to traffic and the onset of myocardial infarction. N Engl J Med 351(17):1721–1730CrossRefPubMed

78.

Thanassoulis G, Peloso GM, Pencina MJ et al (2012) A genetic risk score is associated with incident cardiovascular disease and coronary artery calcium: the Framingham heart study. Circ Cardiovasc Genet 5(1):113–121CrossRefPubMedPubMedCentral

79.

Reinhard W, Trenkwalder T, Schunkert H (2017) Practical guidelines for genetic testing in cardiovascular diseases. Herz 42(5):485–491CrossRefPubMed

80.

Lipshultz SE, Landy DC, Lopez-Mitnik G et al (2012) Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy. J Clin Oncol 30(10):1050–1057CrossRefPubMedPubMedCentral

Titel: Prävention von Herz-Kreislauf-Erkrankungen
verfasst von: Dr. med. J. H. Prochaska
N. Arnold
C. Jünger
T. Münzel
Univ.-Prof. Dr. med. P. S. Wild
Publikationsdatum: 15.01.2018
Verlag: Springer Medizin
Schlagwörter: Koronare Herzerkrankung
KHK in der Hausarztpraxis
Prävention und Rehabilitation in der Kardiologie
Prävention und Screening in der Hausarztpraxis
Erschienen in: Herz / Ausgabe 1/2018
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-017-4669-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Dual antiplatelet therapy after percutaneous coronary intervention for stable CAD or ACS

Antikoagulation und antithrombotische Therapie

Neue Leitlinie: Thrombozytenhemmer oder Antikoagulanzien nach Klappenbehandlung?

Musik, Puls, Herz und der Sport

Malignant pericardial mesothelioma